Pfizer’s US$17 B Buyout of Hospira Paves the Way for a Split
By Heather Cartwright
Pharma Deals Review: Vol 2015 Issue 2 (Table of Contents)
Published: 28 Feb-2015
DOI: 10.3833/pdr.v2015.i2.2093 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Signalling its intent to spin off its global established products(GEP) division in 2017, Pfizer has agreed to acquire Hospira, the market leader in the generic injectables segment, in a deal that values the company at approximately US$17 B inclusive of net debt...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS